BVT Put 175 IDP 20.09.2024/ DE000VD4A7L2 /
6/7/2024 8:44:34 AM | Chg.+0.029 | Bid10:00:04 PM | Ask10:00:04 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.175EUR | +19.86% | - Bid Size: - |
- Ask Size: - |
BIOGEN INC. DL -,000... | 175.00 - | 9/20/2024 | Put |
GlobeNewswire
6/3
Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of ...
GlobeNewswire
5/30
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a R...
GlobeNewswire
5/22
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...
GlobeNewswire
5/16
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...
GlobeNewswire
5/15
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire
4/25
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...
GlobeNewswire
4/23
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire
3/6
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...
GlobeNewswire
3/4
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire
2/23
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...
GlobeNewswire
2/12
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...
GlobeNewswire
2/8
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
GlobeNewswire
12/19/2023
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European C...
GlobeNewswire
12/15/2023
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Fri...